Using Anti-CD38 Monoclonal Antibodies as Treatment in Multiple Myeloma

Measuring Sustained MRD Provides Path to Tailoring Myeloma Therapy

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma therapy.

Newer Approaches Show Potential to Reduce Need for Transplant in NDMM

During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in transplant-eligible multiple myeloma.

Combinations For Transplant-Ineligible NDMM Need Careful Monitoring

During a live event, Taewoong Choi, MD, discussed the potential use of quadruplet in transplant-ineligible multiple myeloma and the need for monitoring for neuropathy with bortezomib.

Frailty Is a Key Consideration in Transplant-Ineligible NDMM

During a live event, Taewoong Choi, MD, discussed the current state of therapy for transplant-ineligible newly diagnosed multiple myeloma.

Newer Trials Explore High-Risk Treatment and MRD in Multiple Myeloma

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials of frontline therapy in multiple myeloma.

Dara-VRd Leads to Sustained MRD Negativity in Newly Diagnosed Myeloma

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the GRIFFIN and PERSEUS clinical trials of quadruplet therapy in multiple myeloma.

Evolving Roles of Transplant and Quadruplet Therapy in Multiple Myeloma

During a Case-Based Roundtable® event, Adam D. Cohen, MD, discussed triplet vs quadruplet options for a patient with transplant eligible multiple myeloma and NCCN recommendations in the first article of a 2-part series.

Dose Modification and Premedications Aid in Tolerability of NDMM Therapy

During a Case-Based Roundtable® event, Stephanie L. Elkins, MD, discussed with participants how they manage toxicity of transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.

Induction and Transplant Outcomes Improve With Quadruplet NDMM Regimen

During a Case-Based Roundtable® event, Stephanie L. Elkins, MD, discussed with participants about quadruplet vs triplet regimens and the goals of deep responses in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.

Benefit of Dara-Rd Maintained Across Age Groups in Transplant-Ineligible NDMM

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the SWOG S0777 and MAIA trials in transplant-ineligible newly diagnosed multiple myeloma in the second article of a 2-part series.

Phase 2 and 3 Transplant-Eligible NDMM Data Build Evidence for Quadruplet Therapy

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the GRIFFIN, MASTER, and PERSEUS trials in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.

Quadruplet Trials Form New Standard in Transplant-Eligible Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Susan Bal, MD, discussed the ongoing significance of the GRIFFIN and MASTER trials in patients with newly diagnosed multiple myeloma, as well as the phase 3 Perseus trial. This is the second of 2 articles based on this event.

Trials Shed Light on Transplant and Maintenance in NDMM

During a Targeted Oncology™ Case-Based Roundtable™ event, Susan Bal, MD, discussed the ongoing significance of the IFM2009, DETERMINATION, and FORTE trials in patients with newly diagnosed multiple myeloma. This is the first of 2 articles based on this event.

Approaches to Manage Frontline Therapy for Multiple Myeloma

During a Targeted Oncology™ Case-Based Roundtable™ event, Surbhi Sidana, MD, discussed with participants how they use quadruplet or triplet frontline regimens for patients with transplant-eligible multiple myeloma. This is the first of 2 articles based on this event.

Supportive Care for Maintenance in Transplant-Ineligible Multiple Myeloma

During a Targeted Oncology case-based roundtable event, Amandeep Godara, MD, discussed the use of maintenance therapy for patients with multiple myeloma. This is the second of 2 articles based on this event.

Adverse Event Management in Transplant-Eligible Multiple Myeloma

During a Targeted Oncology case-based roundtable event, Amandeep Godara, MBBS, discussed with participants the tolerability and optimal use of therapies for newly-diagnosed multiple myeloma.

The Role of Maintenance Daratumumab in Transplant-Eligible Multiple Myeloma

During a live virtual event, Brea C. Lipe, MD, discussed with participants their experiences with maintenance treatment in patients with transplant-eligible multiple myeloma. This is the second of 2 articles based on this event.

Using Frontline Quadruplet Therapy for Transplant-Eligible Multiple Myeloma

During a live virtual event, Brea C. Lipe, MD, discussed what considerations affect the choice of triplet or quadruplet therapy for a patient with transplant-eligible multiple myeloma.

Multiple Myeloma Goals and Risk Factors for Triplet Vs Quadruplet Therapy

During a live virtual event, Caitlin Costello, MD, discussed the rationale for choosing a triplet or quadruplet regimen for patients with transplant-eligible newly diagnosed multiple myeloma.

Part 2: Using Depth of Response and MRD as Goals for Multiple Myeloma

During a live virtual event, Douglas Sborov, MD, MS, discussed the most important goals for treatment and the use of minimal residual disease assessment for a patient with transplant-eligible multiple myeloma.

Part 1: Debating Primary Therapy for Transplant-Eligible Multiple Myeloma

During a live virtual event, Douglas Sborov, MD, MS, discussed the possible treatment regimens for a patient with newly diagnosed multiple myeloma who is eligible for stem cell transplant.

Part 2: Recommending Triplet and Quadruplet Therapies for Multiple Myeloma

During a live virtual event, Mohamed Baljevic, MD, discussed how to select and sequence combination regimens for multiple myeloma while considering eligibility for autologous stem cell transplant.

Part 2: Recommending Triplet and Quadruplet Therapies for Multiple Myeloma

During a live virtual event, Mohamed Baljevic, MD, discussed how to select and sequence combination regimens for multiple myeloma while considering eligibility for autologous stem cell transplant.

Part 1: Assessing Transplant Eligibility Following Treatment for Multiple Myeloma

During a live virtual event, Muhamed Baljevic, MD, discussed what factors determine whether a patient with stage II multiple myeloma could receive autologous stem cell transplant.

Part 2: Daratumumab Shows Greater PFS Benefit Early On in Multiple Myeloma

During a live virtual event, Saad Zafar Usmani, MD, discussed the findings of the CASSIOPEIA and GRIFFIN studies of daratumumab and lenalidomide in patients with newly diagnosed multiple myeloma.

Part 1: Benefit Shown With Transplant and Combination Therapy in Multiple Myeloma

During a live virtual event, Saad Zafar Usmani, MD, discussed 2 studies of drug combinations in patients with multiple myeloma with or without stem cell transplants.